The has a broad clinical and pre-clinical product pipeline. Our differentiated pipeline stands as proof of our ability to identify and address the areas of unmet treatment need and includes three Genmab-created antibodies, out-licensed and developed by partners, that were approved by the U.
Edward E. Elias S. Arnér, Prof. Péter Nagy, Dr. Éva Dóka, Tamás Ditrói and Dr. Katalin Erdélyi at Semmelweis University.
Miklós Geiszt, Semmelweis University, Dept. Janne Lehtiö, Dept. Ed Schmidt, Dept. John L. Christine Winterbourn, University of Otago Christchurch, Centre for Free Radical Research, Christchurch, New-Zealand Methods and equipment Metabolomics and proteomics platform Enzymatic activity, analysis of various metabolites and reactive sulfur species by mass spectrometry and liquid chromatography Thermo LTQ XL mass spectrometer EASY-nLC II nano HPLC · Thermo Scientific UltiMate HPLC with fluorescent detector Cell and tissue culture Investigation of human cancer cell lines — breast, lung, pancreas, melanoma Development of xenograft models in immune deficient mice Examination of neutrophil granulocytes isolated from human blood plasma Processsing of mouse tissue samples for metabolomics and proteomics sterile cell culture hoods, incubator, hypoxic chamber, microscope, etc.
Untreated Metastatic Prostate Cancer - 2021 Prostate Cancer Patient Conference
PubMed Link Doka et al. PubMed Link Akaike et al. PubMed Link Garai et al.
Polysulfide generation activity of MPO by customized fluorescent assay Garai et al. PubMed Link.